Baird Reiterates Outperform Rating on Voyager Therapeutics (VYGR)

Baird analyst Jack Allen reiterated an Outperform rating and $18.00 price target on Voyager Therapeutics (NASDAQ: VYGR).

The analyst commented: "No change to outlook, highlighting potential external catalyst for VY-TAU01 program. Based on Clinical Trials on Alzheimer's Disease conference (CTAD) program it appears that Roche/UCB (RHHBY/UCB, both not covered) will be presenting data from their Phase 2 study testing bepranemab in patients with prodromal–mild Alzheimer's disease at the conference on October 31st. Given the relative similarity in bepranemab and VY-TAU01's mechanisms of action, we note that positive data from the bepranemab program could start to spark enthusiasm for Voyager's tau antibody program as well."

For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.

Shares of Voyager Therapeutics closed at $6.04 yesterday.

You May Also Be Interested In

• BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
• XP Inc eyes US banking license as next business step
• Golden Spike Resources plans name change, share consolidation and C$500K raise